Veru (NASDAQ:VERU) Upgraded by Wall Street Zen to Hold Rating

Veru (NASDAQ:VERU) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued on Sunday.

Other equities analysts have also issued reports about the stock. Oppenheimer cut their price objective on shares of Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Weiss Ratings raised shares of Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Veru in a research report on Thursday, June 4th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.00.

Veru Trading Down 1.1%

VERU traded down $0.03 during trading on Friday, hitting $2.78. The stock had a trading volume of 164,751 shares, compared to its average volume of 351,490. Veru has a 12 month low of $2.05 and a 12 month high of $7.33. The firm has a market cap of $44.62 million, a PE ratio of -3.12 and a beta of -1.19. The company has a 50 day simple moving average of $2.69 and a 200-day simple moving average of $2.50.

Veru (NASDAQ:VERU) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.15. As a group, sell-side analysts anticipate that Veru will post -1.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Veru

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in Veru by 69.3% in the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after purchasing an additional 5,008 shares during the period. Oppenheimer & Co. Inc. boosted its stake in shares of Veru by 3.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 197,876 shares of the company’s stock valued at $423,000 after buying an additional 5,708 shares during the period. Bank of America Corp DE grew its position in Veru by 5.5% during the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after buying an additional 9,637 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Veru during the 3rd quarter worth $38,000. Finally, Blair William & Co. IL raised its holdings in Veru by 26.3% in the 4th quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after acquiring an additional 10,000 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.